The technology company that is integrated into Wyoming confirms ETHEREUM priority on the Bitcoin Treasury, noting the possibility of ETH as a financial tool.
In a statement on Wednesday, Bionexus Gene Lab Corporation confirmed the official approval of the creation of a cabinet focusing on Ethereum. The decision makes it the first entity listed on the Nasdak Stock Exchange to define Eth’s priorities as exclusively strategic origin.
Bionexus adopts the cabinet ethereum
The Wyoming Technology Company has issued an ETHEREUM Whiteper Strategy as well as the March 5 Declaration, which defines the logical basis for setting ETH priorities on the Bitcoin Joint Treasury. The company noted that although Bitcoin provides a strong store of value, ETHEREUM gives a wider benefit given a programmed financial platform.
Bionexus ethereum praised, given its capabilities to generate the return to its owners via Staking, as a basic feature on Bitcoin. However, the technology company realized the increase in adoption by institutional investors in 2024.
Unlike BTC, the white paper highlights that ETH provides an additional stream to gain via Staking. It is worth noting that the POS proof mechanism facilitates asset holders to obtain an annual return of 3-5 %. These Ethereum profits are distinguished from other negative assets, confirming its status as an income generation tool.
Bionexus cited the institutional credibility of ETAREUM after adopting it by leading financial entities, including fidelity and Blackrock. Institutional absorption verifies the capabilities and benefit of ETHEREUM in the long run as a financial tool.
The CEO of Bionexus, Sam Tan, has repeated the goal of the technology company of ETHEREUM strategically as an essential component of its treasury over time. After the approval of the Council, the executive authority issued a bold view to follow up its intention to allocate a large part of its reserves to Ethereum.
Prepare for ethereum cabinet
Tan was not binding on the percentage that the company would allocate to the ETHEREUM Treasury. The Executive Authority indicated that although the team is well ready for the final shift, the exact percentage of Ethereum Treasury is unknown.
Tan revealed continuous discussions on whether Bionexus will start running his auditor’s contract or team with the well -known external service providers. He considers that the option depends on compliance, efficiency and security, although it expressed his optimism as the company is measured by ETHEREUM properties.
Bionexus provides for the decisive role of ETHEREUM in the global financial ecosystem, arguing that it supports a trillion dollars in Stablecoin’s transactions that were implemented annually. It is worth noting that the network displays the settlement layer to the largest Stablecoins Tether (USDT) and USD (USDC).
The white paper by Bionexus refers to the promotion of Pectra Protocol as being able to enhance ETHEREM’s position beyond Altcoin leader. The upgrade will convert the Ethereum network into a reliable long -term commercial infrastructure.
Next challenges
Despite the optimism filmed by the white paper, Pectra’s upgrade suffered from multiple issues during the Sepolia test. Wednesday’s challenges mirror barriers that witnessed during the Holsky test phase.
Bionexus has the initial operations in Asia through a Malaysian company, which is the genome diagnoses in addition to the chemical distribution. Industrial chemical supplies that target space and cars are produced 90 % of the company’s revenue.
Bionexus has recently unveiled the RNA blood -based blood test to help detect infections and cancer early. This sector represents 10 % of the company’s total profits.
Despite the possibilities with Ethereum Treasury, the company led by Tan is fighting financial challenges. The Nasdaq Stock Exchange made a notification to the company in December 2024 on the pretext of not complying with the base to maintain the price of at least one dollar. The parties have reached a temporary exception that is granted the date of May 1 to restore compliance. The company plans to reflect the decision to divide the previous shares by April 7 this year.
The scrutiny of the call calls it made shows that Bionexus made 9.26 million dollars in twelve months revenue with the maximum of its market at $ 5.88 million. The company listed on the Nasdaq Stock Exchange is declining by Ticker BGLC by 4.37 %, raising its share price to 0.3416. A slight improvement in the stock price is not enough to reversed a 59 % decrease for a year, and Marketwatch data appears.
Editorial Credit: RCC_BTN / Shutterstock.com
